Skip to main content
SpringerLink
Log in

Cost effectiveness of nintedanib vs pirfenidone for IPF across Europe

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rinciog C, et al. Nintedanib Cost-Effectiveness in Idiopathic Pulmonary Fibrosis in the Uk. 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PRS27, 29 Oct 2016. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=47761.

  2. Benard S, et al. Nintedanib Cost-Utility in Idiopathic Pulmonary Fibrosis in France. 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PRS45, 29 Oct 2016. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=47993.

  3. Soulard S, et al. Cost-Utility of Nintedanib vs. Pirferidone in the Treatment of Idiopathic Pulmonary Fibrosis in Spain. 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PRS39, 29 Oct 2016. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=48175.

  4. Tritaki G, et al. Pharmacoeconomic Assessment of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis in the Greek Healthcare System. 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSY30, 29 Oct 2016. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=47755.

  5. Ravasio R, et al. Cost Effectiveness Analysis of Pirfenidone for the Treatment of Mild to Moderate Idiopathic Pulmonary Fibrosis (Ipf) Compared to Best Supportive Care and Nintedanib from the Italian Nhs Perspective. 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PRS43, 29 Oct 2016. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=47211.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cost effectiveness of nintedanib vs pirfenidone for IPF across Europe. PharmacoEcon Outcomes News 767, 8–9 (2016). https://doi.org/10.1007/s40274-016-3568-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3568-1

Search

Navigation